Pacira BioSciences Inc. (82P)
XDUS 
Summary
82P Chart
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on biopharmaceutical growth.
Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Pacira BioSciences: Exparel Still Supports My Original Bull Case
PCRX remains a commercial non-opioid pain company built around Exparel, Zilretta, and Iovera. That's why I think the most important catalysts for this stock, for better or worse, will be its upcoming 2026 pipeline readouts. But I reckon that PCRX's overdependence on Exparel remains a factor worth considering, aside from other inherent biotech risks like patents and reimbursement policies, among others.
Pacira BioSciences Inc. (82P) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Pacira BioSciences Inc. ever had a stock split?
Pacira BioSciences Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Frank D. Lee CEO | XDUS Exchange | US6951271005 ISIN |
| US Country | 825 Employees | - Last Dividend | - Last Split | 3 Feb 2011 IPO Date |
Overview
Pacira BioSciences, Inc. is a prominent company operating within the healthcare sector in the United States, focusing on creating innovative non-opioid pain management and regenerative health solutions. Established originally in 2006 and undergoing a name change from Pacira Pharmaceuticals, Inc. to Pacira BioSciences, Inc. in April 2019, the company has dedicated itself to addressing the urgent need for non-opioid therapeutic options. Based in Tampa, Florida, Pacira BioSciences stands at the forefront of developing, manufacturing, marketing, and distributing products designed to offer pain relief and support healing processes without the dependency risks associated with opioids. The company collaborates closely with healthcare practitioners to ensure the accessibility and effectiveness of its solutions, additionally forming strategic partnerships, such as with Aratana Therapeutics, Inc., to enhance its product offerings through development and commercialization agreements.
Products and Services
- EXPAREL
A cutting-edge bupivacaine liposome injectable suspension, EXPAREL is designed for postsurgical pain management. By utilizing a liposomal delivery system, it provides long-lasting pain relief without the need for opioids, offering a significant advantage in the postoperative care landscape.
- ZILRETTA
ZILRETTA is an extended-release injectable suspension formulated with triamcinolone acetonide. Engineered to manage osteoarthritis pain, it provides a sustained therapeutic effect, thereby enhancing patient comfort and mobility over an extended period.
- iovera° system
The iovera° system represents a groundbreaking approach to pain management through handheld cryoanalgesia technology. It works by applying controlled doses of cold to targeted nerves to temporarily reduce pain without drugs, making it an innovative non-opioid treatment option for various conditions.
- NOCITA
Developed through a strategic partnership with Aratana Therapeutics, Inc., NOCITA is another bupivacaine liposome injectable suspension offered by Pacira. It is specially designed for managing post-surgical pain in pets, extending the company’s non-opioid pain management solutions to the veterinary field.
